LENZ — LENZ Therapeutics, Inc.

LENZ Therapeutics Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: $16.7 million, translating to a net loss per share of $0.59, compared to a net loss of $10.2 million ($0.38 per share) in Q3 2024.
• Operating Expenses: Total operating expenses increased to $31.4 million, a 44% increase from Q2, primarily driven by a ramp-up in selling, general, and administrative (SG&A) expenses.
• Cash Position: As of the end of Q3, LENZ had approximately $324 million in cash, cash equivalents, and marketable securities, bolstered by a direct placement raising over $123 million in October.
• Product Launch: Initial product sales of VIZZ began in October, with over 5,000 prescriptions filled within the first month of launch.

2. Strategic Updates and Business Highlights

• FDA Approval: VIZZ, the first aceclidine-based eye drop for presbyopia, received FDA approval in July 2025, ahead of its PDUFA date.
• Launch Strategy: The company is focused on building awareness and confidence among eye care professionals (ECPs) through sampling and direct engagement. Over 2,500 doctors have prescribed VIZZ, with 40% writing multiple prescriptions.
• Direct-to-Consumer Campaign: Scheduled for Q1 2026, featuring Sarah Jessica Parker as the spokesperson, aimed at driving consumer demand.
• Sampling Strategy: Over 70,000 samples distributed to approximately 7,000 ECP offices, with a focus on ensuring broad access to the product.

3. Forward Guidance and Outlook

• Sales Projections: The company is optimistic about VIZZ's adoption, with plans to transition to a consumer-focused marketing strategy in early 2026.
• Financial Guidance: Expected SG&A expenses for 2026 are projected to be between $80 million to $100 million, with G&A expenses around $20 million to $25 million.
• Market Positioning: LENZ aims to establish VIZZ as a standard of care for presbyopia, leveraging positive early feedback from ECPs and patients.

4. Bad News, Challenges, or Points of Concern

• Initial Revenue: No product revenues were recorded in Q3 as sales began only in October, making it difficult to assess immediate financial performance.
• Side Effects: Although initial feedback on efficacy is positive, there are concerns regarding transient side effects (redness and stinging) that could affect patient experience and adoption.
• Market Competition: The company faces competition from existing treatments for presbyopia, and the long-term success of VIZZ will depend on its ability to differentiate itself in a crowded market.

5. Notable Q&A Insights

• ECP Engagement: The sales team is actively working with key opinion leaders (KOLs) to set realistic expectations regarding VIZZ's efficacy and side effects.
• Prescription Trends: While early adoption is promising, the company is cautious about sharing detailed prescription trends until more data is available.
• Patient Demographics: Initial users of VIZZ are primarily in the 45-65 age range, with a notable skew towards females, aligning with expectations for presbyopia treatment.
• E-Pharmacy vs. Retail: The initial distribution of prescriptions has been skewed towards e-pharmacies, with traditional retail pharmacies coming online gradually.

Overall, LENZ Therapeutics is in a strong position following the launch of VIZZ, with a solid financial foundation and positive early reception from the medical community, although challenges remain in terms of managing side effects and competition.